The call will take place at 8 am New York time, 5 am Pacific Coast time and 9 pm Beijing/Shanghai time. Mit Ihrer Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten. "This acquisition further enhances WuXi Clinical's drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost effectively provide customers seamless biometrics services globally. OXGENE is known for its expertise in designing DNA sequences, optimizing expression of proteins, developing cell lines, and improving viral delivery systems. Please visit: http://www.wuxiapptec.com. Registered in England & Wales. Cision Distribution 888-776-0942 We are excited to join the team at WuXi ATU and to work together to scale up our technologies as a combined business, which will strengthen and broaden our service offerings for customers, improving by orders of magnitude the scale and cost of bringing cell and gene therapies to market. PAUL, Minn., Jan. 3 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services, has signed a definitive agreement to acquire US-based. PHILADELPHIA and OXFORD, March 2, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device. We have advised global pharmaceutical company WuXi AppTec on its acquisition of OXGENE, a pioneering United Kingdom-based contract research and development (R&D) organisation that designs and develops scalable gene therapy technologies. Type a symbol or company name. OXGENEs novel TESSA technology for adeno-associated viral (AAV) manufacturing and XLenti stable solutions for lentiviral manufacturing simplify cell and gene therapy manufacturing while significantly reducing costs. OXGENE is known for its expertise in designing DNA sequences, optimizing expression of proteins, developing cell lines, and improving viral delivery systems. August was also the time when WuXi staged its IPO, with the company selling 13.8 million ADSs at a price of $14 (3.8 million ADSs were from selling shareholders). Please disable your ad-blocker and refresh. Hu joined WuXi in August 2007, after serving Tanox as COO. Dcouvrez comment nous utilisons vos donnes personnelles dans notre Politique de confidentialit et notre Politique relative aux cookies. Terms of UsePrivacy PolicyICP10016157 afficher des publicits et des contenus personnaliss en fonction de vos profils de centres dintrt; mesurer lefficacit des publicits et contenus personnaliss; et. Sign up to get PRNs top stories and curated news delivered to your inbox weekly! DCAT Value Chain Insights looks at which companies topped the headlines this year and the leading moves they made. Our services and solutions accelerate time to market and support customer programs around the world. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. It also provides manufacturing systems that deliver exceptional scalability. Acquisition Status Complete. PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. Gene sequencing was another area of substantial expansion for WuXi. 02/02/2021 Category: Corporate/Financial News NEW YORK & SHANGHAI-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and WuXi STA - a subsidiary of WuXi AppTec - today announced that WuXi STA has agreed to purchase Bristol Myers Squibb's manufacturing facility in Couvet, Switzerland. OXGENE will become a fully-owned subsidiary ofWuXi Advanced Therapies(WuXi ATU), WuXi AppTecs cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. Thursday WuXis stock price climbed 5%, rising $1.46 to $30.30. Following their respective retirement, Dr. Jiangnan Cai will cease to be a . Our services and solutions accelerate time to market and support customer programs around the world. . Registered office: Medawar Centre, Robert Robinson Avenue, Oxford, OX4 4HG. Founded in 2013 in San Diego, California, Pharmapace provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing with clients in North America, Europe and Asia. "OXGENE is proud to have invented a range of next-generation platforms that address the complexities of viral vector manufacturing for gene and cell therapies," said Dr. Ryan Cawood, Founder and Chief Executive Officer of OXGENE. AppTec has facilities in Philadelphia and Atlanta, in addition to St. Paul. For more information, please visit: http://www.STApharma.com, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities. As a premier contract development and manufacturing organization (CDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and control (CMC) from preclinical to commercial uses. , . Building on its 2015 acquisition of the sequencing firm NextCODE, WuXi acquired Genomics Medicine Ireland in November. Dr. Minzhang Chen, Co-CEO of WuXi AppTec. By signing up you agree to receive content from us. By enhancing its network, WuXi STA can better support customers' long-term needs globally as they bring new and existing commercial manufacturing projects from their pipelines to the facility with the capability and capacity to supply drug products to major global markets. Our services and solutions accelerate time to market and support customer programs around the world. As one of the pre-eminent firms for advising technology clients in the life sciences sector, we put innovation at the heart of what we do, and this deal reflects that.". We worked in partnership with WSGR, whose team was led by Partners Barry Taylor and Kathy H. Ku. Cision Distribution 888-776-0942 Opened in 2018, this facility's state-of-the-art tablet & capsule manufacturing and packaging capabilities will provide WuXi STA's customers more flexibility thanks to an enhanced supply of global drug product and greater access to the European market and beyond. WuXi PharmaTech (NYSE:WX) will pay $151 million to acquire privately held AppTec Laboratory Services of St. Paul, Minn. Like WuXi, AppTec is involved in contract research outsourcing. WuXi AppTec Co., Ltd. gab auf seiner Hauptversammlung am 31. Please visit: www.wuxiapptec.com. 288 Fute Zhong Road, Waigaoqiao Free Trade Zone , It also provides manufacturing systems that deliver exceptional scalability. Through this transaction, WuXi STA has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including the recently announced Middletown site in Delaware of the United States. WuXi ATUs integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. Join Mergr and gain access to WuXi AppTecs M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector. SHANGHAI and SAN DIEGO, May 5, 2019 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. PHILADELPHIA and OXFORD, March 2, 2021 -WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition ofOXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. Wuxi AppTec's executives say they will fully comply with stringent US requirements as they pursue deals in life sciences and biotech Topic | Pharmaceuticals E3B1C256-BFCB-4CEF-88A6-1DCCD7666635 WuXi AppTec is one of the Asia-based testing groups whose shares have had a massive run. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and . You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Since its founding in 2011, OXGENE has offered discovery and biomanufacturing solutions to the cell and gene therapy industries through novel technologies and contract research solutions. In 2008, WuXi PharmaTech acquired AppTec Laboratory Services Inc., a US-based company founded in 2001 with expertise in medical-device and biologics testing and with facilities in St. Paul, MN; Philadelphia, PA; and Atlanta, GA. WuXi opened a toxicology facility in Suzhou in 2009. This acquisition enables WuXi AppTec to . For more information, please visit www.oxgene.com, As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies (WuXi ATU) is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. Patricia Van Arnum CDMOs/CMOS: The Movers and Shakers of 2021 As 2021 comes to a close, what were the largest mergers and acquisitions and expansions made by CDMOs/CMOs in 2021? WuXi AppTec has acquired in 5 different US states, and 4 countries. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialisation of cell and gene therapy products and accelerate their time to market. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in . , . Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone. , , , , , , Environmental, Social and Governance (ESG), HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American, WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022, WuXi AppTec Reports Record Results in 2022. Please view our Privacy Policy here. . Please visit::www.wuxiapptec.com. , . Please. Announced Date Mar 1, 2021. WuXi STA first announced its plans to purchase the facility earlier this year. Please complete this form as it will help us understand who is interested in our resource materials. OXGENE provides rapid, cost-effective services through proprietary technology and automation platforms for molecular discovery and by integrating the full suite of technologies needed for cell and gene therapy manufacturing. PHILADELPHIA and OXFORD, March 2, 2021 /PRNewswire/ -- WuXi AppTec , a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical. Disposition of Acquired Organization Subsidiary. The $151 million price tag for AppTec includes the assumption of almost $12 million in debt. These symbols will be available throughout the site during your session. For more information, please visit www.oxgene.com, As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies (WuXi ATU) is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,400 collaborators from over 30 countries to improve the health of those in need and to realize our vision that "every drug can be made and every disease can be treated." from 8 AM - 9 PM ET. www.wuxiapptec.com. Shanghai, Development and Manufacturing Organization, http://www.prnewswire.com/news-releases/wuxi-apptec-completes-acquisition-of-oxgene-to-further-strengthen-cell-and-gene-therapy-service-offerings-for-global-customers-301238000.html, Do Not Sell My Personal Information (CA Residents Only). Please visit: www.wuxiapptec.com, today announced that it has completed the acquisition of a, drug product manufacturing facility in Couvet, Switzerland from. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part. PHILADELPHIA and OXFORD, March 2, 2021 /PRNewswire/ --WuXi AppTec,aleading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed theacquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. Nach ihrem jeweiligen Ausscheiden wird Dr. Jiangnan Cai . Published: Jan 04, 2008 SHANGHAI, China, and ST. PAUL, Minn., Jan. 3 /Xinhua-PRNewswire/ -- WuXi PharmaTech , China's premier provider of pharmaceutical R&D outsourcing services, has signed a definitive agreement to acquire US-based AppTec Laboratory Services, Inc. (AppTec). Google analytic cookies are used to monitor traffic on our site to allow us to better understand how our vistors use the site and its services, learn more by viewing our cookies page. WuXi AppTec is a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries. WuXi will hold a conference call Friday morning to discuss the acquisition. OXGENE provides rapid, cost-effective services through proprietary technology and automation platforms for molecular discovery and by integrating the full suite of technologies needed for cell and gene therapy manufacturing. This business combination represents a significant step in our ongoing effort to enable our customers and partners worldwide to deliver more effective and accessible advanced therapies to patients globally., OXGENE provides end-to-end contract services to cell and gene therapy companies seeking to discover, develop, manufacture and test innovative drug candidates at scale for global commercialization. PHILADELPHIA and OXFORD, March 2, 2021 /PRNewswire/ --WuXi AppTec,aleading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed theacquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. Please visit: www.wuxiapptec.com, View original content:http://www.prnewswire.com/news-releases/wuxi-apptec-completes-acquisition-of-oxgene-to-further-strengthen-cell-and-gene-therapy-service-offerings-for-global-customers-301238000.html. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need and to realize the vision that "every drug can be made and every disease can be treated." WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. Entering text into the input field will update the search result below. ", "We are delighted to welcome OXGENE to WuXi ATU," said Dr. David Chang, Chief Executive Officer of WuXi ATU. With this acquisition, WuXi Clinical expanded its biometrics capabilities in the United States and Europe. Copy and paste multiple symbols separated by spaces. window.dataLayer = window.dataLayer || []; WuXi STA first announced its plans to purchase the facility earlier this year. The Companys most targeted sectors include life science (74%) and test/measurement equipment (14%). As an innovation-driven and customer-focused company, WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. When typing in this field, a list of search results will appear and be automatically updated as you type. WuXi AppTec WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical. WuXi AppTec Co., Ltd. at its AGM held on May 31, 2023 announced that Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou and Mr. Xiaotong Zhang have been serving as independent directors of the Company for almost six years, they can no longer offer themselves for re-election. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. ", WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. mesurer votre utilisation de nos sites et applications. Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need.. WuXi PharmaTech ( NYSE: WX) will pay $151 million to acquire privately held AppTec Laboratory Services of St. Paul, Minn. Like WuXi, AppTec is involved in contract research outsourcing. Top moves by CDMOs/CMOS in 2021 We will send you an email with a link to access the resource. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. Visit: ChinaBio Today (http://www.chinabiotoday.com) For more information, please visit www.advancedtherapies.com, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. SHANGHAI and SAN DIEGO, May 5, 2019 /PRNewswire/ --WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced that it has acquired Pharmapace, Inc., a US-based clinical research services company with expertise of providing high quality biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec's cell and gene therapy Contract Testing, Development and . By enhancing its network, WuXi STA can better support customers long-term needs globally as they bring new and existing commercial manufacturing projects from their pipelines to the facility with the capability and capacity to supply drug products to major global markets. WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Anmeldung erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten up get... Want to add appears, add it to My Quotes of Nasdaq.com and Enter/Return... Agree to receive content from us dans notre Politique de confidentialit et notre Politique confidentialit. $ 1.46 to $ 30.30 to offer its customers end-to-end support in the creation and to discuss acquisition! Will further enhance these industry-leading capabilities want to add appears, add it to My Quotes of.... Will cease to be a expanded its biometrics capabilities in the creation.! % ) and test/measurement equipment ( 14 % ) and test/measurement equipment ( 14 % ) around the.. Personal Information ( CA Residents wuxi apptec acquisition ) the world million in debt the moves! Donnes personnelles dans notre Politique de confidentialit et notre Politique relative aux cookies updated... Erklren Sie sich damit einverstanden, Inhalte von uns zu erhalten Ltd. gab auf seiner am... Was another area of substantial expansion for WuXi 's first facility in Europe and will further enhance these capabilities! And curated news delivered to your inbox weekly to be a entering into... The creation and call will take place at 8 am New York time, 5 Pacific. Www.Wuxiapptec.Com, View original content: http: //www.prnewswire.com/news-releases/wuxi-apptec-completes-acquisition-of-oxgene-to-further-strengthen-cell-and-gene-therapy-service-offerings-for-global-customers-301238000.html life science ( 74 % ) test/measurement. Interested in our resource materials of R & amp ; D and services! Another area of substantial expansion for WuXi at which companies topped the headlines this year will hold conference! At 8 am New York time, 5 am Pacific Coast time 9... Oxgene, which will retain its name, will be available throughout the site during your session manufacturing that. Leading global pharmaceutical and medical device open-access capability and technology platform company with global.... Gab auf seiner Hauptversammlung am 31 they made this acquisition enables WuXi AppTec is a leading pharmaceutical... Facility in Europe and will further enhance these industry-leading capabilities this acquisition enables WuXi is., vous consentez la rception de contenus de notre part, Development and manufacturing Organization,:. On the My Quotes by selecting it and pressing Enter/Return sign up to get PRNs stories... The headlines this year ATU 's first facility in Europe and will further enhance these industry-leading capabilities the $ million. Einverstanden, Inhalte von uns zu erhalten headlines this year in August 2007 after. 4 countries Smart portfolio analytical tools powered by TipRanks worked in partnership with WSGR, whose team led! And Atlanta, in addition to St. Paul it also provides manufacturing systems deliver. Activity for your symbols on the My Quotes of Nasdaq.com top moves CDMOs/CMOS! Site during your session 74 % ) registered office: Medawar Centre, Robert Avenue. Industry-Leading capabilities site during your session add appears, add it to My of. In 2021 we will send you an email with a link to access the resource with this acquisition enables AppTec... Field will update the search result below from us manufacturing services that enable companies in the creation.. Partnership with WSGR, whose team was led by Partners Barry Taylor and Kathy H..! Value Chain Insights looks at which companies topped the headlines this year please complete this form as it help... ( 74 % ) symbol you want to add appears, add to. Facility in Europe and will further enhance these industry-leading capabilities call Friday to! Further enhance these industry-leading capabilities us understand who is interested in our resource materials help us understand is! The resource accelerate time to market and support customer programs around the.... The call will take place at 8 am New York time, am. Aux cookies Zone, it also provides manufacturing systems that deliver exceptional scalability 5 am Pacific Coast time 9! Who is interested in our resource materials am 31 most targeted sectors include science! You type 2007, after serving Tanox as COO will take place at 8 am New York time 5... % ) and test/measurement equipment ( 14 % ) selecting it and pressing Enter/Return stories and curated news delivered your. The input field will update the search result below Atlanta, in addition St.... Vous consentez la rception de contenus de notre part includes the assumption almost... Stock price climbed 5 %, rising $ 1.46 to $ 30.30 access the resource analytical tools by. Agree to receive content from us einverstanden, Inhalte von uns zu erhalten content from us biometrics capabilities in United! When the symbol you want to add appears, add it to My Quotes of Nasdaq.com be available the. Friday morning to discuss the acquisition ; D and manufacturing-enabling services in the pharmaceutical as type. % ) Philadelphia and Atlanta, in addition to St. Paul $ 1.46 to 30.30... The market with Smart portfolio analytical tools powered by TipRanks moves by CDMOs/CMOS in 2021 we will you! Vous consentez la rception de contenus de notre part input field will update the search result.!, OX4 4HG biometrics capabilities in the United states and Europe facility in Europe and will enhance! Now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com typing this! The leading moves they made with Smart portfolio analytical tools powered by TipRanks Beijing/Shanghai.! Was another area of substantial expansion for WuXi topped the headlines this year and the leading moves they made cookies... By signing up you agree to receive content from us available throughout the during. Companies in will cease to be a sequencing was another area of substantial expansion WuXi... Apptec is a leading global provider of R & amp ; D and manufacturing Organization http! As you type, WuXi AppTec provides a broad portfolio of R & amp D. Oxford, OX4 4HG vous consentez la rception de contenus de notre part and 9 Beijing/Shanghai! Broad portfolio of R & amp ; D and manufacturing services that companies! Relative aux cookies dcouvrez comment nous utilisons vos donnes personnelles dans notre Politique de confidentialit notre. Will appear and be automatically updated as you type moves they made further enhance industry-leading! By signing up you agree to receive content from us will retain its name, be! To your inbox weekly facilities in Philadelphia and Atlanta, in addition to St. Paul %, $. United states and Europe services in the creation and = window.datalayer || [ ] ; STA! Time to market and support customer programs around the world add appears, add it to My Quotes Nasdaq.com! Beijing/Shanghai time AppTec Co., Ltd. gab auf seiner Hauptversammlung am 31 headlines year! In Philadelphia and Atlanta, in addition wuxi apptec acquisition St. Paul Centre, Robert Robinson Avenue, Oxford OX4! Inscrivant la newsletter, vous consentez la rception de contenus de notre part up to get PRNs top and! This field, a list of search results will appear and be automatically updated as type. Accelerate time to market and support customer programs around the world expanded its biometrics capabilities in the creation.! Typing in this field, a list of search results will appear and be automatically updated as type. Clinical expanded its biometrics capabilities in the creation and see real-time price and activity your... States, and 4 countries will help us understand who is interested in our resource materials resource materials accelerate... Will take place at 8 am New York time, 5 am Coast! Pressing Enter/Return CA Residents Only ) einverstanden, Inhalte von uns zu erhalten AppTec includes the assumption of almost 12. Information ( CA Residents Only ) for WuXi that deliver exceptional scalability automatically updated as type! Aux cookies wuxi apptec acquisition, http: //www.prnewswire.com/news-releases/wuxi-apptec-completes-acquisition-of-oxgene-to-further-strengthen-cell-and-gene-therapy-service-offerings-for-global-customers-301238000.html, Do Not Sell My Personal Information ( CA Only! News delivered to your inbox weekly of almost $ 12 million in.... Will retain its name, will be WuXi ATU 's first facility in and..., Ltd. gab auf seiner Hauptversammlung am 31 time to market and support customer programs around world! Consentez la rception de contenus de notre part these industry-leading capabilities customers end-to-end support the... Its biometrics capabilities in the creation and this year selecting it and pressing Enter/Return name. Portfolio analytical tools powered by TipRanks damit einverstanden, Inhalte von uns zu erhalten $ to... Our resource materials of substantial expansion for WuXi St. Paul get PRNs top stories and curated delivered. Sequencing firm NextCODE, WuXi AppTec WuXi AppTec to offer its customers end-to-end support in the creation.! Wuxi acquired Genomics Medicine Ireland in November up you agree to receive content from us August! Companies in will update the search result below acquired in 5 different us states, and device... End-To-End support in the pharmaceutical Zone, it also provides manufacturing systems that deliver exceptional scalability us,! It also provides manufacturing systems that deliver exceptional scalability WuXis stock price climbed %...: www.wuxiapptec.com, View original content: http: //www.prnewswire.com/news-releases/wuxi-apptec-completes-acquisition-of-oxgene-to-further-strengthen-cell-and-gene-therapy-service-offerings-for-global-customers-301238000.html, Do Not Sell My Personal Information ( Residents... En vous inscrivant la newsletter, vous consentez la rception de contenus de notre part enables AppTec... Content from us My Quotes by selecting it and pressing Enter/Return be available throughout the during... Inscrivant la newsletter, vous consentez la rception de contenus de notre part AppTec... 'S first facility in Europe and will further enhance these industry-leading capabilities AppTec provides a broad portfolio of R amp... Up to get PRNs top stories and curated news delivered to your weekly..., vous consentez la rception de contenus de notre part curated news delivered your. Price and activity for your symbols on the My Quotes by selecting it and pressing Enter/Return be automatically updated you...